Yupelri

Active Ingredient(s): Revefenacin
FDA Approved: * November 9, 2018
Pharm Company: * THERAVANCE BIOPHARMA
Category: Lungs (Pulmonary)

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.The main symptoms of COPD inc... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Yupelri 175 ug/3ml Respiratory (Inhalation) Solution

NDC: 49502-806

Labeler:

Mylan Specialty L.p.